Effectiveness of satralizumab in a real-world clinical setting in Japan: Interleukin-6 receptor inhibition in neuromyelitis optica spectrum disorder: A six-month interim analysis of a multicenter medical chart review.

Fujihara K, Isobe N, Miyamoto K, Niino M, Nakahara J, Hattori S, Yamamoto M, Kawachi I, Matsui N, Nohara C, Kokubun N, Chihara N, Misu T, Okada K, Yamashita K, Nagatsuka T, Adachi H, Nakashima I.

Open source

DOI: 10.1016/j.msard.2025.106384
Published: 2025-03-19
Container: Mult Scler Relat Disord
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.msard.2025.106384,
  title = {Effectiveness of satralizumab in a real-world clinical setting in Japan: Interleukin-6 receptor inhibition in neuromyelitis optica spectrum disorder: A six-month interim analysis of a multicenter medical chart review.},
  author = {Fujihara K and  Isobe N and  Miyamoto K and  Niino M and  Nakahara J and  Hattori S and  Yamamoto M and  Kawachi I and  Matsui N and  Nohara C and  Kokubun N and  Chihara N and  Misu T and  Okada K and  Yamashita K and  Nagatsuka T and  Adachi H and  Nakashima I.},
  year = {2025},
  journal = {Mult Scler Relat Disord},
  doi = {10.1016/j.msard.2025.106384},
  url = {https://doi.org/10.1016/j.msard.2025.106384}
}

RIS

TY  - JOUR
TI  - Effectiveness of satralizumab in a real-world clinical setting in Japan: Interleukin-6 receptor inhibition in neuromyelitis optica spectrum disorder: A six-month interim analysis of a multicenter medical chart review.
AU  - Fujihara K
AU  -  Isobe N
AU  -  Miyamoto K
AU  -  Niino M
AU  -  Nakahara J
AU  -  Hattori S
AU  -  Yamamoto M
AU  -  Kawachi I
AU  -  Matsui N
AU  -  Nohara C
AU  -  Kokubun N
AU  -  Chihara N
AU  -  Misu T
AU  -  Okada K
AU  -  Yamashita K
AU  -  Nagatsuka T
AU  -  Adachi H
AU  -  Nakashima I.
PY  - 2025
JO  - Mult Scler Relat Disord
DO  - 10.1016/j.msard.2025.106384
UR  - https://doi.org/10.1016/j.msard.2025.106384
ER  -

APA

K, F., N, I., K, M., M, N., J, N., S, H., M, Y., I, K., N, M., C, N., N, K., N, C., T, M., K, O., K, Y., T, N., H, A., & I., N. (2025). Effectiveness of satralizumab in a real-world clinical setting in Japan: Interleukin-6 receptor inhibition in neuromyelitis optica spectrum disorder: A six-month interim analysis of a multicenter medical chart review.. Mult Scler Relat Disord. https://doi.org/10.1016/j.msard.2025.106384

Source records

europe-pmc · retrieved 2026-09-26T15:52:18.675Z